{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-091188","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2026-08-05T20:43:14+00:00","discovered_at":"2026-08-05T20:44:00.278746+00:00","generated_at":"2026-08-05T20:44:05.179173+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Coherus Q2 2026 net loss narrows to $33.3M; LOQTORZI revenue up 37% YoY to $13.6M","bullets":["LOQTORZI net revenue $13.6M in Q2 2026, up 37% YoY from $10.0M and 15% sequentially from $11.8M.","GAAP net loss from continuing ops $33.3M ($0.22 diluted EPS) vs $44.9M ($0.39) in Q2 2025.","Non-GAAP net loss $30.1M ($0.19) vs $39.0M ($0.34) in prior year; total net revenue $14.3M.","R&D expenses fell to $21.4M from $26.3M; SG&A fell to $21.0M from $26.0M on cost reductions.","Pipeline: tagmokitug and casdozokitug trials enrolling; initial data readouts expected 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-091188","json":"https://secwatch.observer/filing/0001104659-26-091188.json","markdown":"https://secwatch.observer/filing/0001104659-26-091188.md","text":"https://secwatch.observer/filing/0001104659-26-091188.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000110465926091188/0001104659-26-091188-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000110465926091188/chrs-20260805x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:44:05.179173+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}